Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ubong Peters

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
ERJ Open Research|August 25, 2020
Physiological signature of late-onset nonallergic asthma of obesityAnne E Dixon, Ubong Peters, Ryan Walsh, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|October 29, 2020
Altered airway mechanics in the context of obesity and asthmaJason H T Bates, Ubong Peters, Nirav Daphtary, et al.
Respirology (Carlton, Vic.)|January 30, 2019
BMI but not central obesity predisposes to airway closure during bronchoconstrictionUbong Peters, Meenakumari Subramanian, David G Chapman, et al.
Annals of the American Thoracic Society|August 3, 2021
Air Trapping versus Atelectasis in Obesity: Relationship to Late-Onset Nonallergic Asthma and AgingSwati A Bhatawadekar, Ubong Peters, Ryan R Walsh, et al.
Respirology (Carlton, Vic.)|January 6, 2021
Central airway collapse is related to obesity independent of asthma phenotypeSwati A Bhatawadekar, Ubong Peters, Ryan R Walsh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast CancerKomal L Jhaveri, Melissa K Accordino, Philippe L Bedard, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b studyPhilippe L Bedard, Komal L Jhaveri, Melissa K Accordino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical ModelsDejan Juric, Kyung Song, Radia M Johnson, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
ERJ Open Research|August 25, 2020
Physiological signature of late-onset nonallergic asthma of obesityAnne E Dixon, Ubong Peters, Ryan Walsh, et al.
Journal of Applied Physiology (Bethesda, Md. : 1985)|October 29, 2020
Altered airway mechanics in the context of obesity and asthmaJason H T Bates, Ubong Peters, Nirav Daphtary, et al.
Respirology (Carlton, Vic.)|January 30, 2019
BMI but not central obesity predisposes to airway closure during bronchoconstrictionUbong Peters, Meenakumari Subramanian, David G Chapman, et al.
Annals of the American Thoracic Society|August 3, 2021
Air Trapping versus Atelectasis in Obesity: Relationship to Late-Onset Nonallergic Asthma and AgingSwati A Bhatawadekar, Ubong Peters, Ryan R Walsh, et al.
Respirology (Carlton, Vic.)|January 6, 2021
Central airway collapse is related to obesity independent of asthma phenotypeSwati A Bhatawadekar, Ubong Peters, Ryan R Walsh, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 5, 2024
Phase I/Ib Trial of Inavolisib Plus Palbociclib and Endocrine Therapy for <i>PIK3CA</i>-Mutated, Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced or Metastatic Breast CancerKomal L Jhaveri, Melissa K Accordino, Philippe L Bedard, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2025
Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b studyPhilippe L Bedard, Komal L Jhaveri, Melissa K Accordino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical ModelsDejan Juric, Kyung Song, Radia M Johnson, et al.
Pageof 2